Pluripotency of human embryonic and induced pluripotent stem cells for cardiac and vascular regeneration.
Pluripotency of human embryonic and induced pluripotent stem cells for cardiac and vascular regeneration.
复制标题
DOI：
10.1160/th09-07-0507
复制
发表时间：
2010-07
影响因子：
6.7
通讯作者：
Boheler KR
中科院分区：
文献类型：
--
作者：
Boheler KR
心脏和血管异常和疾病综合征是人类发育和衰老过程中死亡的主要原因。为了确定先天性缺陷的原因，并在老龄化人口中对抗这种流行病，必须建立新的模型进行科学调查，必须开发新的疗法。多能干细胞生物学的最新进展为解决这些问题提供了新的希望。特别重要的是通过强制表达两到四种转录因子从成体组织和器官产生诱导多能（iPS）细胞。此外，在表型上与胚胎干（ES）细胞无法区分的iPS细胞可以从任何患者产生。这种独特的能力，再加上来自患有先天性和遗传缺陷的患者的样本，病因不明，应该允许创建新的模型系统，促进科学研究。此外，患者特异性细胞的产生应克服目前阻碍与其他多能干细胞及其衍生物相关的治疗应用的许多免疫学限制。本文的目的是讨论心脏和血管疾病，并展示如何利用iPS细胞来克服该领域面临的一些最重要的科学和临床障碍。
Cardiac and vascular abnormalities and disease syndromes are major causes of death both during human development and with aging. To identify the cause of congenital defects and to combat this epidemic in the aging population, new models must be created for scientific investigation and new therapies must be developed. Recent advances in pluripotent stem cell biology offer renewed hope for tackling these problems. Of particular importance has been the creation of induced pluripotent (iPS) cells from adult tissues and organs through the forced expression of two to four transcription factors. Moreover, iPS cells, which are phenotypically indistinguishable from embryonic stem (ES) cells, can be generated from any patient. This unique capacity when coupled with samples from patients who have congenital and genetic defects of unknown aetiology should permit the creation of new model systems that foment scientific investigation. Moreover, creation of patient-specific cells should overcome many of the immunological limitations that currently impede therapeutic applications associated with other pluripotent stem cells and their derivatives. The aims of this paper will be to discuss cardiac and vascular diseases and show how iPS cells may be employed to overcome some of the most significant scientific and clinical hurdles facing this field.